Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
phenothiazine derivative |
| gptkbp:ATCCode |
N05AA02
|
| gptkbp:brand |
gptkb:Levoprome
gptkb:Nozinan |
| gptkbp:CASNumber |
60-92-4
|
| gptkbp:chemicalFormula |
C19H24N2OS
|
| gptkbp:contraindication |
coma
bone marrow depression CNS depression hypersensitivity to phenothiazines |
| gptkbp:developedBy |
gptkb:France
|
| gptkbp:discoveredBy |
gptkb:Paul_Charpentier
|
| gptkbp:drugClass |
typical antipsychotic
|
| gptkbp:eliminationHalfLife |
15-30 hours
|
| gptkbp:excretion |
urine
feces |
| https://www.w3.org/2000/01/rdf-schema#label |
Levomepromazine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
1950s
|
| gptkbp:mechanismOfAction |
muscarinic receptor antagonist
dopamine receptor antagonist alpha-adrenergic receptor antagonist histamine receptor antagonist |
| gptkbp:metabolism |
liver
|
| gptkbp:molecularWeight |
328.47 g/mol
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:PubChem_CID |
4058
|
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
weight gain
QT prolongation hypotension sedation extrapyramidal symptoms anticholinergic effects |
| gptkbp:synonym |
gptkb:Nozinan
gptkb:methotrimeprazine levoprome |
| gptkbp:UNII |
U0D3YWU464
|
| gptkbp:usedFor |
nausea
schizophrenia vomiting pain management palliative care psychosis agitation |
| gptkbp:bfsParent |
gptkb:Antidepressants
|
| gptkbp:bfsLayer |
6
|